Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Regeneron today and set a price target of $860.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tazeen Ahmad has given his Buy rating due to a combination of factors, emphasizing that the failed LAG-3 melanoma study was not a core pillar of the Regeneron investment case. She notes that the market had treated the LAG-3 program more like an upside optionality, so the setback does not materially alter her long-term outlook or valuation framework, and any share price weakness may offer an attractive entry point for investors.
Ahmad highlights that Regeneron retains a robust pipeline and multiple near-term catalysts, including regulatory decisions and pivotal data readouts across key programs such as Eylea HD and several cemdisiran-based indications. She also underscores the company’s solid financial profile and earnings trajectory, supporting an unchanged $860 price objective and reinforcing the view that the current share price underestimates Regeneron’s diversified growth opportunities.
Ahmad covers the Healthcare sector, focusing on stocks such as Regeneron, ACADIA Pharmaceuticals, and Argenx Se. According to TipRanks, Ahmad has an average return of 3.5% and a 53.96% success rate on recommended stocks.